These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 23161787

  • 1. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.
    Di Stefano AL, Enciso-Mora V, Marie Y, Desestret V, Labussière M, Boisselier B, Mokhtari K, Idbaih A, Hoang-Xuan K, Delattre JY, Houlston RS, Sanson M.
    Neuro Oncol; 2013 May; 15(5):542-7. PubMed ID: 23161787
    [Abstract] [Full Text] [Related]

  • 2. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    Ghasimi S, Wibom C, Dahlin AM, Brännström T, Golovleva I, Andersson U, Melin B.
    J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
    [Abstract] [Full Text] [Related]

  • 3. Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients.
    Viana-Pereira M, Moreno DA, Linhares P, Amorim J, Nabiço R, Costa S, Vaz R, Reis RM.
    Mol Biol Rep; 2020 Feb; 47(2):877-886. PubMed ID: 31721021
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D, POLA Network.
    Neuro Oncol; 2019 Dec 17; 21(12):1519-1528. PubMed ID: 31832685
    [Abstract] [Full Text] [Related]

  • 7. Genome-wide association study identifies five susceptibility loci for glioma.
    Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre JY, Hoang-Xuan K, El Hallani S, Idbaih A, Zelenika D, Andersson U, Henriksson R, Bergenheim AT, Feychting M, Lönn S, Ahlbom A, Schramm J, Linnebank M, Hemminki K, Kumar R, Hepworth SJ, Price A, Armstrong G, Liu Y, Gu X, Yu R, Lau C, Schoemaker M, Muir K, Swerdlow A, Lathrop M, Bondy M, Houlston RS.
    Nat Genet; 2009 Aug 17; 41(8):899-904. PubMed ID: 19578367
    [Abstract] [Full Text] [Related]

  • 8. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul.
    Neuro Oncol; 2014 Jul 17; 16(7):914-23. PubMed ID: 24470545
    [Abstract] [Full Text] [Related]

  • 9. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.
    Walsh KM, Rice T, Decker PA, Kosel ML, Kollmeyer T, Hansen HM, Zheng S, McCoy LS, Bracci PM, Anderson E, Hsuang G, Wiemels JL, Pico AR, Smirnov I, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, Sicotte H, Eckel-Passow JE, Wiencke JK, Jenkins RB, Wrensch MR.
    Neuro Oncol; 2013 Aug 17; 15(8):1041-7. PubMed ID: 23733245
    [Abstract] [Full Text] [Related]

  • 10. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
    Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idbaih A, Houlston RS, Sanson M.
    Acta Neuropathol; 2018 May 17; 135(5):743-755. PubMed ID: 29460007
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M.
    BMC Cancer; 2019 Oct 17; 19(1):968. PubMed ID: 31623593
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. New insights into susceptibility to glioma.
    Liu Y, Shete S, Hosking FJ, Robertson LB, Bondy ML, Houlston RS.
    Arch Neurol; 2010 Mar 17; 67(3):275-8. PubMed ID: 20212223
    [Abstract] [Full Text] [Related]

  • 16. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC, Zhang KN, Chang YZ, Wu F, Liu YQ, Zhao Z, Wang KY, Chang YH, Jiang T, Wang YZ.
    Carcinogenesis; 2019 Oct 16; 40(10):1229-1239. PubMed ID: 31157866
    [Abstract] [Full Text] [Related]

  • 17. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z, Lan Y, Wang L, Ge J, Wang J, Liu F, He Z, Zhang H, Luo M, Lin D, Tan Y, Xu Y, Luo T.
    BMC Cancer; 2020 Nov 09; 20(1):1072. PubMed ID: 33167941
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Genetic advances in glioma: susceptibility genes and networks.
    Liu Y, Shete S, Hosking F, Robertson L, Houlston R, Bondy M.
    Curr Opin Genet Dev; 2010 Jun 09; 20(3):239-44. PubMed ID: 20211558
    [Abstract] [Full Text] [Related]

  • 20. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
    Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Paterra R, Marie Y, Rahimian A, Finocchiaro G, Houlston RS, Hoang-Xuan K, Idbaih A, Delattre JY, Mokhtari K, Sanson M.
    Br J Cancer; 2014 Nov 11; 111(10):2024-32. PubMed ID: 25314060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.